5.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.82
Aprire:
$5.75
Volume 24 ore:
825.78K
Relative Volume:
0.67
Capitalizzazione di mercato:
$299.65M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-1.4209
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
-8.75%
1M Prestazione:
+4.38%
6M Prestazione:
+100.69%
1 anno Prestazione:
-49.31%
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VSTM
Verastem Inc
|
5.84 | 299.65M | 3.64M | -87.37M | -86.46M | -4.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-24 | Reiterato | H.C. Wainwright | Buy |
2024-12-31 | Reiterato | BTIG Research | Buy |
2024-09-30 | Iniziato | Guggenheim | Buy |
2023-11-21 | Ripresa | BTIG Research | Buy |
2023-09-27 | Iniziato | B. Riley Securities | Buy |
2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
2022-09-07 | Ripresa | Alliance Global Partners | Buy |
2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
2022-03-09 | Iniziato | Truist | Buy |
2021-07-01 | Iniziato | Alliance Global Partners | Buy |
2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
2018-07-13 | Iniziato | BTIG Research | Buy |
2018-05-02 | Iniziato | Seaport Global Securities | Buy |
2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
2017-09-07 | Reiterato | H.C. Wainwright | Buy |
2017-04-13 | Iniziato | Oppenheimer | Outperform |
2017-03-24 | Reiterato | H.C. Wainwright | Buy |
2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2015-09-29 | Downgrade | Jefferies | Buy → Hold |
2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
2015-09-09 | Iniziato | Raymond James | Strong Buy |
2015-05-12 | Reiterato | UBS | Buy |
2015-04-08 | Iniziato | H.C. Wainwright | Buy |
2015-01-23 | Reiterato | ROTH Capital | Buy |
2014-07-08 | Ripresa | Oppenheimer | Perform |
2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Verastem Oncology Reports Progress in Cancer Treatments - TipRanks
Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Yahoo Finance
Revolutionary Cancer Drug Achieves Complete Response in Colorectal Cancer Study - Stock Titan
Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India
Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia
H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada
Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada
H.C. Wainwright lifts Verastem stock price target to $10 - Investing.com India
Royal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $14.00 - Defense World
RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating -March 21, 2025 at 08:40 am EDT - Marketscreener.com
BTIG maintains $20 target, Buy rating on Verastem stock By Investing.com - Investing.com Canada
Verastem: Q4 Earnings Snapshot - Midland Daily News
Verastem director Brian Stuglik sells shares worth $4,121 By Investing.com - Investing.com Australia
Verastem Unveils Strategic Plans in New Presentation - TipRanks
Verastem Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verastem, Inc. SEC 10-K Report - TradingView
Verastem Inc. (VSTM) reports earnings - Quartz
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Bluefield Daily Telegraph
Verastem director Robert Gagnon sells shares worth $1,973 By Investing.com - Investing.com Australia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Verastem CEO sells shares worth $1,695 By Investing.com - Investing.com South Africa
Verastem director Robert Gagnon sells shares worth $1,973 - Investing.com
Verastem director Brian Stuglik sells shares worth $4,121 - Investing.com
Verastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Verastem Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Verastem to Present at Keystone Symposia on PI3 Kinase - AOL.com
Verastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM) - Seeking Alpha
Rhumbline Advisers Acquires 10,352 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge - Morningstar
Verastem (VSTM) Expected to Announce Earnings on Thursday - Defense World
Objective long/short (VSTM) Report - Stock Traders Daily
Verastem Inc (NASDAQ: VSTM) Stock Forecast: Bearish Expectations Portend -120.34% Downside In 2025 - Stocks Register
Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Business Wire
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
When the Price of (VSTM) Talks, People Listen - Stock Traders Daily
Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex
Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):